logo-loader
viewCircassia Pharmaceuticals PLC

Circassia completes managerial changes as Johnson becomes executive chairman

Steve Harris is stepping down as chief executive after thirteen years

Circassia Pharmaceuticals PLC -
Circassia's Duaklir is an inhaled COPD treatment

Circassia Pharma PLC (LON:CIR) has undertaken a major overhaul of its board and senior management.

Steve Harris is stepping down as chief executive of the respiratory drug specialist after thirteen years, with Ian Johnson appointed executive chairman as his replacement.

Johnson is best known from his time as executive chairman of Bioquell and is currently the non-executive chair of Redcentric and on the board at Ergomed.

Garry Watts is also joining the drug group as a senior independent director following existing chairman Francesco Granata’s decision to retire.

In August, Circassia appointed Johnathan Emms to the new role of chief operating officer.

Steve Harris said: "After many years leading Circassia, the company has undergone major transformation and I am delighted we have attracted such a high calibre leader as Ian to take the business to the next level, alongside our recently appointed highly experienced Chief Operating Officer, Jonathan Emms.

“With our preparations well advanced for the forthcoming US launch of Duaklir, the ongoing establishment of our new Chinese sales team in the marketplace and our growing commercial presence in Europe, we look forward to Jonathan leading our commercial strategy. 

Circassia also repeated earlier guidance that full-year 2019 revenues will be between £60 - £65mln (2018: £48.3mln) with cash outflows the second half to drop 'drastically'.

Quick facts: Circassia Pharmaceuticals PLC

Price: 25.5 GBX

LSE:CIR
Market: LSE
Market Cap: £95.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

RNS

Holding(s) in Company

3 days, 12 hours ago

Holding(s) in Company

5 days, 13 hours ago

Holding(s) in Company

1 week, 1 day ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

1 week, 5 days ago

2 min read